Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension

Boehringer Ingelheim3,045 enrolled

Overview

Study to assess the effect of Telmisartan on diastolic and systolic blood pressure and to establish the effect on patient's quality of life scores.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

3,045

Conditions

Hypertension

Interventions

Low dose of telmisartanDRUG

High dose of telmisartanDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 93 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Stage I essential Hypertension (diastolic blood pressure 90-99 mmHg, and/or systolic blood pressure 140-159 mmHg) * Signed informed consent form Exclusion Criteria: \- Females of childbearing potential

Outcomes

Primary Outcomes

Change in diastolic blood pressure

Time frame: Pre-dose, up to 6 weeks after start of treatment

Change in systolic blood pressure

Time frame: Pre-dose, up to 6 weeks after start of treatment

Changes from baseline in the quality of life (QOL) scores by patient self-assessment

Time frame: Pre-dose, 6 weeks after start of treatment

Secondary Outcomes

Assessment of blood pressure control rate

Time frame: Up to 6 weeks after start of treatment

Assessment of systolic blood pressure response rate

Time frame: Up to 6 weeks after start of treatment

Assessment of diastolic blood pressure response rate

Time frame: Up to 6 weeks after start of treatment

Change from baseline in pulse pressure

Time frame: Pre-dose, up to 6 weeks after start of treatment

Number of patients with adverse events

Time frame: Up to 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.